Dow Jones Industrial Average ETF vs 10X Genomics Inc — how do they compare? Dow Jones Industrial Average ETF trades at $512.08 (market cap $45.20B), while 10X Genomics Inc trades at $79.3 (market cap $10.07B). The key difference: Dow Jones Industrial Average ETF is far larger — about 4.5× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Dow Jones Industrial Average ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and 10X Genomics Inc for 92 Days on average.
| DIA | TXG | |
|---|---|---|
Market Cap | $45.20B | $10.07B |
Volume | 4,095,368 | 5,657,286 |
52-Week High | $542.79 | $97.74 |
52-Week Low | $451.37 | $11.48 |
Typical Hold Time | 103 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.02, down 0.68% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF provides exposure to the 30 blue-chip Dow Jones Industrial Average components, offering diversified large-cap value. Recent dividend distributions in 2026 provide income, while broader market sentiment reflects caution amid economic uncertainty and Federal Reserve policy focus.
The outlook for DIA hinges on the performance of the Dow 30 constituents, with potential upside from strong corporate earnings but risks from high bond yields and market volatility. As a passive ETF, its value tracks the index, making macroeconomic trends and interest rate expectations key drivers. Current technical weakness near support at $509 suggests near-term pressure, though long-term investors may find stability in its blue-chip holdings.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →